Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease
Year: 2017
Type: review
Source: Experimental Neurology
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Michael J. Fox Foundation for Parkinson's Research, Pfizer, GlaxoSmithKline, CHDI Foundation, Teva Pharmaceutical Industries, JPB Foundation, Parkinson's NSW, Adamas Pharmaceuticals, IDP Foundation, Lundbeckfonden, National Institutes of Health, National Health and Medical Research Council, Biotieteiden ja Ympäristön Tutkimuksen Toimikunta, National Institute of Neurological Disorders and Stroke, National Institute for Dementia Research
Awards: Cellular effects of glucocerebrosidase (GBA) mutations in Lewy body diseases, Clinical Coordination Center for STEADY-PD3, G6485530970, G6492698944, Tackling the complex pathogenesis of non-Alzheimer dementias and motor neurodegenerative disorders, G8295532686, Frontotemporal dementia and motor neurodegenerative syndromes, G8536267541, Determinants of Dopaminergic Neuron Degeneration in Parkinson's Disease
OpenAlex ID: W2741297747
